financetom
Business
financetom
/
Business
/
Fortinet Insider Sold Shares Worth $32,079,517, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Fortinet Insider Sold Shares Worth $32,079,517, According to a Recent SEC Filing
Mar 12, 2025 12:51 AM

03:19 AM EDT, 03/12/2025 (MT Newswires) -- Michael Xie, Director, Vice President, Engineering and Chief Technology Officer, on March 11, 2025, sold 326,784 shares in Fortinet ( FTNT ) for $32,079,517. Following the Form 4 filing with the SEC, Xie has control over a total of 56,999,568 common shares of the company, with 11,000,068 shares held directly and 45,999,500 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1262039/000141588925007744/xslF345X05/form4-03122025_120314.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Immix Biopharma's NXC-201 Trial Meets Primary Endpoint in AL Amyloidosis
Immix Biopharma's NXC-201 Trial Meets Primary Endpoint in AL Amyloidosis
Jun 3, 2025
03:30 PM EDT, 06/03/2025 (MT Newswires) -- Immix Biopharma ( IMMX ) said the US multisite clinical trial evaluating its NXC-201 cell therapy in relapsed or refractory AL Amyloidosis achieved its primary endpoint of complete response. NXC-201 treatment resulted in a 70% complete response rate, and all of the patients in the trial had baseline relapsed or refractory AL Amyloidosis...
EU antitrust regulators escalate Visa, Mastercard probe, documents show
EU antitrust regulators escalate Visa, Mastercard probe, documents show
Jun 3, 2025
BRUSSELS, June 3 (Reuters) - EU antitrust regulators are asking retailers and payments companies whether a standardized summary of fees by Visa and Mastercard ( MA ) and more transparency on the charges would address their concerns, according to documents seen by Reuters. The latest questionnaires sent on Tuesday, which came nearly two months after the last batch, suggest that...
EU antitrust regulators escalate Visa, Mastercard probe, documents show
EU antitrust regulators escalate Visa, Mastercard probe, documents show
Jun 3, 2025
BRUSSELS (Reuters) -EU antitrust regulators are asking retailers and payments companies whether a standardized summary of fees by Visa and Mastercard ( MA ) and more transparency on the charges would address their concerns, according to documents seen by Reuters. The latest questionnaires sent on Tuesday, which came nearly two months after the last batch, suggest that EU regulators have...
Copyright 2023-2026 - www.financetom.com All Rights Reserved